

Code Brown: Incidence of Diarrhea in Critically Ill Patients on Defined Enteral Formulas.

Rumberger L et al. 2014 Clinical Nutrition Week, Abstract 1835637.

OBJECTIVE: Determine if there was a difference in the incidence of diarrhea between two immunonutrition formulas used in the Surgical Intensive Care Unit SICU.

METHODS:

Consecutive 3 month periods of retrospective chart review

Formula A = IMPACT® Peptide 1.5 formula (n=52)


Formula B = PIVOT® 1.5 Cal formula (n=61)

- No significant differences in demographic factors including age, gender, and indication for admission between the two groups.
- No statistical difference in the following:
 - Number of C. difficile tests ordered
 - Number of antibiotics, laxatives and antimotility agents received.


Need For Rectal Tube to Manage Diarrhea

IMPACT® PEPTIDE 1.5

Pivot® 1.5 Cal



Yes No



IMPACT® Peptide 1.5 contains:

- Lower percentage of carbohydrates
- Lower osmolality
- Higher MCT:LCT ratio

All of which was thought to contribute to the lower incidence of diarrhea and need for rectal tubes.

Formula	Days of Diarrhea
IMPACT® Peptide 1.5	1.42
Pivot® 1.5 Cal	4.25

p<0.001

Summary prepared by Nestlé Health Science.

PIVOT® is a registered trademark of Abbott Laboratories.

IMPACT® Peptide 1.5 is a trademark of Société des Produits Nestlé S.A., Vevey, Switzerland.

Unless otherwise indicated, all trademarks are owned Société des Produits Nestlé S.A., Vevey, Switzerland. ©2026 Nestlé.

NEST-15676-0726